U.S. FDA Grants Fast Track Designation to Novavax' H7N9

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
U.S. FDA Grants Fast Track Designation to Novavax' H7N9 Influenza Virus-Like Particle Vaccine Candidate Adjuvanted With Matrix-M(TM)

GAITHERSBURG, Md., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX ), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Novavax' H7N9 Virus-Like Particle Vaccine Candidate (H7N9 VLP) adjuvanted with Matrix-M™. The H7N9 VLP is being developed under the company's contract with the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) (Contract No. HHSO100201100012C) for the development of Novavax' recombinant vaccines to address seasonal influenza and influenza strains with pandemic potential.

"The FDA's Fast Track Designation for our H7N9 VLP underscores the FDA's recognition of the risk of H7N9 influenza, the lack of any approved vaccines for H7N9 influenza, and the strength of our H7N9 VLP," said Stanley C. Erck, President and CEO of Novavax. "This achievement is another example of the capabilities of our technology platform, the commitment of our people, and the importance of our collaboration with BARDA."

In November 2013, Novavax published the first clinical data for any H7N9 Influenza vaccine candidate in The New England Journal of Medicine, which reported positive Phase 1 clinical data from its H7N9 VLP (adjuvanted with a saponin-based adjuvant), in 284 adult subjects, within 180 days of initiating its H7N9 VLP program, an unprecedented achievement in the vaccine industry. The data from this Phase 1 study, along with the positive data released in September 2014 from a Phase 2 trial of 610 subjects, establish Novavax' H7N9 VLP as a leading H7N9 vaccine candidate under development in the industry today.

The Fast Track Drug Development Program was established under the FDA Modernization Act of 1997. A Fast Track designation is intended for products that treat serious or life-threatening diseases or conditions, and that demonstrate the potential to address unmet medical needs for such diseases or conditions. The program is intended to facilitate development and expedite review of drugs to treat serious and life-threatening conditions so that an approved product can reach the market expeditiously. Specifically, Fast Track designation facilitates meetings to discuss all aspects of development to support licensure and it provides the opportunity to submit sections of a Biologics License Application (BLA) on a rolling basis as data become available, which permits the FDA to review modules of the BLA as they are received instead of waiting for the entire NDA submission. In addition, accelerated approval status (licensure based on a surrogate endpoint) and priority review (6 month review versus standard 10 month review) are potential benefits that may be available to Novavax' H7N9 VLP in the future.

About H7N9 Avian Influenza

Following recognition of the first human infections with H7N9 avian-origin influenza and their attendant severity in March 2013, public health officials from around the world called for immediate and preemptive development of surveillance, diagnostic and clinical intervention tools in the event that the H7N9 virus becomes transmissible among humans. According to Dr. Keiji Fukuda, Assistant Director-General for Health, Security and Environment at the WHO, there is high concern over potential for H7N9 to gain sustainable person-to-person transmissibility. Dr. Fukada noted that over a two-month period in China, as many H7N9 cases occurred as H5N1 cases occurring over a 10 year period. Additionally, molecular genetic changes occurred, suggesting adaptation of the virus to humans. After a quiescent period during the 2014 summer months, several new human cases of H7N9 disease have been reported since the beginning of October 2014, prompting concerns and expectations over the virus reemerging in human populations in the coming winter season.

About the Novavax HHS-BARDA Contract

The contract was originally awarded in February 2011, with funding of up to $97 million over an initial base period ending in February 2014, and subsequently extended to September 2014. Through the second quarter of 2014, Novavax recognized approximately $65 million in revenue since the inception of the contract. During the contract's 43-month base period, Novavax has been developing and testing its novel recombinant virus-like particle (VLP) influenza vaccines to address BARDA's commitment to advancing recombinant-based technology as a component of pandemic preparedness. In September 2014, BARDA exercised the option period of the contract and extended the period of performance through September 2016. The milestones under the option period are focused on activities leading up to initiation of Phase 3 clinical trials. Through the second quarter of 2014, the company recognized approximately $65 million in revenue since the inception of the contract.

About Novavax

Novavax, Inc. (Nasdaq: NVAX ) is a clinical-stage biopharmaceutical company creating novel vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant protein nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases. Additional information about Novavax is available on the company's website, novavax.com.

Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2013 filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000 David Schull or Andrea Flynn, Ph.D. Russo Partners, LLC 212-845-4271

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LASIK Cost Math Deserves a Careful Second Look Today

Updated Category News Views 188

Thirty years of lens purchases can become a nasty tab Contact-lens spending has a funny way of staying invisible until somebody stacks the receipts into one ugly pile. A new cost-of-vision analysis from the surgeon advisory board of BestLASIKSurgeons.com says the average American contact-lens wearer may spend between $22,500 and $30,000 on corrective eyewear across 30...

Continue Reading
AMPERA Joins Berto to Power Future Energy Innovations

Updated Category News Views 296

The Power Play You Didn't See Coming AMPERA and Berto just made a move that could stir up some serious waves in the energy sector. They've inked a business combination deal set to push advanced energy technology to the forefront. With AMPERA's valuation clocking in at roughly $900 million, this partnership aims to bring cutting-edge power solutions from concept to market....

Continue Reading
Visual Cipher Bench Exposes AI Agents' Hidden Rule Gap

Updated Category News Views 81

Forty little black-and-white puzzles just threw a bucket of cold water on the autonomous-agent sales pitch. Einsia AI’s Navers Lab says its new Visual Cipher Bench found that the best result among eight frontier models was only 26.7%, with no tested configuration clearing 30%. That is not a minor blemish. It is a reminder that a model can sound clever, use tools, and...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 139

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 85

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 264

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading
Unilumin's APEC 2026 Showcase Is a Useful Field Test

Updated Category News Views 65

Few sales pitches get stress-tested by a thousand journalists, a major airport, and a leaders' summit all at once. That is the useful part of Unilumin's role as an official sponsor of APEC 2026 in Shenzhen. The company says its LED systems were installed across summit venues, the media center, transportation hubs, and city landmarks as the 33rd APEC Economic Leaders'...

Continue Reading
Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 192

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
Texas Restaurants Get a New Read on Customer Demand

Updated Category News Views 34

Texas restaurant owners are being handed a sharper flashlight, and frankly it is overdue. HundredX and the Texas Restaurant Association have launched a pilot that gives TRA members access to the HundredX Restaurant Insights Platform, aiming to bring customer and market intelligence to the independent operators and regional chains that usually cannot pay big-company prices...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 173

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading

Top 5 Most Recently Viewed Articles

Therap Services Implements SMS Security Features for Users

Updated Category News Views 172

Enhancing Security and User Control with SMS Features Therap Services is at the forefront of improving data protection in the realm of electronic documentation solutions specifically tailored for the Long-Term Services and Supports (LTSS) and Home and Community-Based Services (HCBS). By recently rolling out SMS-based password reset and two-factor authentication (2FA)...

Continue Reading
Understanding Stakeholder Disclosures in Student Property Sector

Updated Category News Views 127

Key Insights into Stakeholder Disclosure Regulations Stakeholder disclosures play a crucial role in maintaining transparency in the market, particularly in industries like real estate and student accommodations. Understanding these requirements is essential for investors and companies alike. This discussion focuses on the significance of disclosures concerning relevant...

Continue Reading
VestGen Wealth Partners Expands Leadership for Enhanced Services

Updated Category News Views 130

VestGen Expands Leadership Team to Elevate Client Services In a strategic move aimed at enhancing its operations and service offerings, VestGen Wealth Partners, LLC has announced a significant expansion of its leadership team. This includes the appointment of Rob Bondiman as the National Head of Advisors and Matt LaLonde as the inaugural Director of Insurance, heading...

Continue Reading
Toll Brothers Launches Stunning New Townhome Community

Updated Category News Views 304

Introducing Toll Brothers at East Cobb Walk Toll Brothers, Inc., renowned for its premium housing, has unveiled its new community, now available for sale. This exciting release presents a rare opportunity for homebuyers to invest in beautiful townhomes within an attractive neighborhood. Luxury Townhomes with Modern Designs The new community, Toll Brothers at East Cobb...

Continue Reading
Understanding Assura Plc's Recent Public Disclosure

Updated Category News Views 129

Public Disclosure Overview Understanding public disclosures is crucial for investors and stakeholders in the financial market. In this article, we will explore Assura Plc's latest public disclosure under Rule 8.3 of the Takeover Code. The company revealed significant information about interests that represent over 1% of certain securities. These disclosures aim to provide...

Continue Reading